Pomalidomide NDC 70095-060

NDC codes

FDA NDC Directory

Product NDC (as listed)70095-060Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70095-0060Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70095-060-01	70095006001	21 CAPSULE in 1 BOTTLE (70095-060-01)Marketed from Aug 31, 2026
70095-060-02	70095006002	100 CAPSULE in 1 BOTTLE (70095-060-02)Marketed from Aug 31, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pomalidomide
Generic name (nonproprietary): pomalidomide
Active ingredients: Pomalidomide — 4 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Sun Pharmaceutical Industries, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210232
Marketing start: Aug 31, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 70095-060_5a6cdeaf-06a4-d9db-e063-6294a90a906eSPL ID 5a6cdeaf-06a4-d9db-e063-6294a90a906eSPL set ID 3c222961-5398-4185-b2d0-defe90230094RxCUI 1369718, 1369726, 1369730, 1369734UNII D2UX06XLB5
Pharmacologic class: Thalidomide Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470095006001 followed by a unit qualifier and the quantity

Package 70095-0060-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 1, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Pomalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients: in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy (1.1). 1.1 Multiple Myeloma Pomalidomide capsules, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last ther…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210232

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210232
Product	Strength	Form · route	Labeler	Product NDC
Pomalidomide	Pomalidomide 1 mg/1	CapsuleOral	Sun Pharmaceutical Industries, Inc.	70095-057
Pomalidomide	Pomalidomide 2 mg/1	CapsuleOral	Sun Pharmaceutical Industries, Inc.	70095-058
Pomalidomide	Pomalidomide 3 mg/1	CapsuleOral	Sun Pharmaceutical Industries, Inc.	70095-059